Protagenic Therapeutics (NASDAQ:PTIX) Announces Quarterly Earnings Results

Protagenic Therapeutics (NASDAQ:PTIX) released its quarterly earnings data on Monday. The company reported ($0.24) earnings per share (EPS) for the quarter, Zacks reports.

Protagenic Therapeutics Price Performance

Shares of NASDAQ PTIX opened at $0.25 on Wednesday. The company has a market capitalization of $1.78 million, a price-to-earnings ratio of -0.20 and a beta of 0.43. Protagenic Therapeutics has a 1-year low of $0.18 and a 1-year high of $1.87. The business has a 50-day moving average of $0.30 and a 200-day moving average of $0.48.

About Protagenic Therapeutics

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.